U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...